Personalis And 2 Other AI Healthcare Stocks To Watch

Big Tech companies have been raising record amounts in the bond market this year to fund heavier spending on AI, even as borrowing costs rise and investors question how quickly those projects will pay off. That tug of war between huge capital flows and nervous sentiment creates an opening. This article looks at three healthcare AI stocks that are using that same computing wave to try to solve real medical problems.

The stocks below are a short sample of the theme. The full screen surfaced 31 more companies with equally compelling AI in healthcare stories that are not covered here. To identify your own highest conviction ideas in this space, head straight to the Transformative Artificial intelligence (AI) Healthcare Stocks screener.

Personalis (PSNL)

Personalis uses high depth genomic sequencing plus AI driven analytics to help oncologists and drug developers detect residual cancer earlier and fine tune treatment decisions. This positions the company within the broader healthcare AI theme.

Personalis, Inc. develops AI enabled cancer genomic tests like NeXT Personal and ImmunoID NeXT for MRD detection, tumor profiling and pharma research, and has a market cap of about US$1.69b.

"Expanding Medicare coverage for NeXT Personal in breast and lung cancer surveillance, along with active submissions for IO monitoring and neoadjuvant breast cancer, points to a larger pool of reimbursed tests that could lift clinical revenue and support margin recovery from current low levels."

One relatively quiet shift in how these AI driven tests are paid for could potentially change the economics of Personalis much faster than currently anticipated.

If that reimbursement shift feels underpriced, walk through the full narrative for Personalis to see how Personalis could accelerate or stall as those volumes and margins evolve.

Insmed (INSM)

Insmed leans on a growing respiratory medicines franchise today, while its AI driven protein engineering work hints at a very different drug design toolkit tomorrow. This is why it earns a spot in an AI focused healthcare screen.

"Continued expansion of BRINSUPRI into the growing diagnosed U.S. bronchiectasis population of at least 500,000 patients, with company guidance for more than $1.25 to $1.4b in 2026 BRINSUPRI revenue and a raised peak sales view of more than $7b, points to further potential scaling of Insmed revenue and operating leverage."

What happens to that operating leverage if a single assumption about how quickly new patients come onto treatment proves too optimistic?

Insmed develops treatments for serious and rare diseases, with respiratory drugs like ARIKAYCE driving its US$1.52b in rare disease therapy revenue, and an AI driven protein engineering program targeting future medicines on top of a roughly US$23.9b market value.

If that patient ramp risk is what you keep circling back to, read the full narrative for Insmed to see how Insmed’s AI work could accelerate or cushion the story.

Mettler-Toledo International (MTD)

Mettler-Toledo International leans heavily on precision instruments, but its LabX software and AI driven imaging tools quietly turn raw lab readings into cleaner, faster decisions for diagnostics and drug research, which is exactly why it earns a place in an AI healthcare screen.

Mettler-Toledo International Inc. supplies precision instruments and lab software that support diagnostics, drug R&D and quality control, with AI linked LabX and imaging layered on top of a broad hardware base. Revenue is spread across U.S. Operations at about US$1.63b, Western European Operations at roughly US$1.14b, Swiss Operations at around US$1.08b, Chinese Operations near US$1.01b and Other Operations at about US$870 million. The group has a market value of roughly US$34.53b.

"Expanding bioprocessing and broader biopharma activity, including facility expansions, GLP‑1 manufacturing and reshoring related investments, is expected to create further demand for Mettler Toledo International’s process analytics and industrial equipment along the biopharma value chain."

The real swing factor is how one pressure on future pricing power collides with that AI heavy lab workflow demand over the next few years.

If that pricing pressure is what you keep coming back to, walk through the full narrative for Mettler-Toledo International for how Mettler-Toledo International could see AI demand and margins decoupling.

Seeking Alternatives Before They Take Off

Fresh opportunities do not wait. By the time momentum headlines arrive, early entry points can be gone. Scan these under the radar ideas now, while it matters, and get in early.

• Hunt for potential turnarounds with cleaner balance sheets and disciplined cash flows using the curated 42 high quality undervalued stocks before the crowd reacts to the next breakout wave.
• Target income ideas where yield and resilience intersect through a focused list of 6 dividend fortresses before prices move and yields start dropping.
• Track the infrastructure behind AI’s surge by reviewing carefully filtered 53 AI infrastructure stocks while these enablers of future capacity expansion remain under the radar.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com